Top

BMC Pediatrics

Published in:

Open Access 01-12-2017 | Case report

A child with resistant Kawasaki disease successfully treated with anakinra: a case report

Authors: J. Sánchez-Manubens, A. Gelman, N. Franch, S. Teodoro, J. R. Palacios, N. Rudi, J. Rivera, J. Antón

Published in: BMC Pediatrics | Issue 1/2017

Abstract

Background

Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%. In spite of its effectiveness, some children do not respond to this therapy and still develop coronary aneurysms (CAA). The optimal treatment for IVIG non-responsive patients remains controversial although corticoids have been suggested to be an effective treatment in some patients. For those patients still resistant to IVIG and corticoids, interleukin-1 receptor antagonists (IL-1RA) such anakinra could be an alternative.

Case presentation

We present a 3 year-old Caucasian patient with KD without cardiac complications but with important resistance to treatment. After becoming resistant to IVIG and corticoids, anakinra proved to be an effective treatment.

Conclusions

To our knowledge, this is the first report of the utility of IL-1RA in refractory KD without coronary impairment. The patient fulfilled the classical criteria for KD and, after becoming resistant to first and second line treatments, anakinra proved to be an effective treatment. Further studies are required to determine if this is an effective treatment option for other cases of resistant Kawasaki disease.

Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, Endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics. 2004;114:1708–33. doi:10.1542/peds.2004-2182.CrossRefPubMed

Sánchez-Manubens J, Bou R, Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun. 2014;48–49:113–7. doi:10.1016/j.jaut.2014.01.010.CrossRefPubMed

Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163:521–6. doi:10.1016/j.jpeds.2013.01.022.CrossRefPubMed

Brogan P, Levin M. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease. Evid Based Med. 2013;18:217–8. doi:10.1136/eb-2013-101264.CrossRefPubMed

Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011;158:644–649. e1. doi:10.1016/j.jpeds.2010.10.012

Sonoda K, Mori M, Hokosaki T, Yokota S. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 2014;164:1128–1132. e1. doi:10.1016/j.jpeds.2014.01.020.

Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012;161:506–512. e1. doi:10.1016/j.jpeds.2012.02.048.

Cohen S, Tacke CE, Straver B, et al. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis. 2012;71:2059–61. doi:10.1136/annrheumdis-2012-201658.CrossRefPubMed

Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2014;12:26. doi:10.1186/1546-0096-12-26.CrossRefPubMedPubMedCentral

10.

Hoang LT, Shimizu C, Ling L, et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med. 2014;6:541. doi:10.1186/s13073-014-0102-6.CrossRefPubMedPubMedCentral

11.

Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J. 2013;13:52–9. doi:10.1038/tpj.2011.45.CrossRefPubMed

12.

Lee Y, Schulte DJ, Shimada K, et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125:1542–50. doi:10.1161/CIRCULATIONAHA.111.072769.CrossRefPubMedPubMedCentral

13.

Weng K-P, Hsieh K-S, Ho T-Y, et al. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ J. 2010;74:544–51. http://www.ncbi.nlm.nih.gov/pubmed/20081319. Accessed 27 Jan 2016.CrossRefPubMed

14.

Leung DY, Cotran RS, Kurt-Jones E, et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet (London, England). 1989;2:1298–302. http://www.ncbi.nlm.nih.gov/pubmed/2480498. Accessed 27 Jan 2016.CrossRef

15.

Suzuki H, Uemura S, Tone S, et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr. 1996;155:291–6. http://www.ncbi.nlm.nih.gov/pubmed/8777922. Accessed 27 Jan 2016.CrossRefPubMed

Title: A child with resistant Kawasaki disease successfully treated with anakinra: a case report
Authors: J. Sánchez-Manubens
A. Gelman
N. Franch
S. Teodoro
J. R. Palacios
N. Rudi
J. Rivera
J. Antón
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Pediatrics / Issue 1/2017
Electronic ISSN: 1471-2431
DOI: https://doi.org/10.1186/s12887-017-0852-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A child with resistant Kawasaki disease successfully treated with anakinra: a case report

Abstract

Background

Case presentation

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Rigour and Rapport: a qualitative study of parents’ and professionals’ experiences of joint agency infant death investigation

Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity

Hepatic paragonimiasis in a 15-month-old girl: a case report

The role of family and school-level factors in bullying and cyberbullying: a cross-sectional study

Using LMS tables to determine waist circumference and waist-to-height ratios in Colombian children and adolescents: the FUPRECOL study

Risk factors and implications of progressive coronary dilatation in children with Kawasaki disease